Using this definition, there were 21 (9.2%) obesity pharmacotherapy users in the semaglutide arm and six (6.1%) in the placebo arm during the extension, including GLP‐1 receptor agonist use in 14 (6.1%) and four (4.0%) participants in the semaglutide and placebo arms, respectively (including semaglutide up to 1.0 mg and liraglutide up to 3.0 mg). The gene discussed is GLP1R; the disease is obesity disorder.